Christoph Kessel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christoph Kessel has a total of 322 co-authors. Here are the top co-authors by number of shared publications:
- Dirk Foell
Department of Paediatric Rheumatology and Immunology, University Hospital Münster, Münster, Germany
16 shared publications Helmut Wittkowski
Department of Pediatric Rheumatology and Immunology University Children's Hospital Muenster Muenster Germany
15 shared publicationsDirk Foell
Department of Pediatric Rheumatology and Immunology, University Hospital Muenster, Muenster, Germany
11 shared publications- Dirk Holzinger
Department of Pediatrics III, Pediatric Rheumatology and Immunology, University of Duisburg-Essen, Essen, Germany; Department of Nursing, Midwifery and Therapy Sciences, Bochum University of Applied Sciences, Bochum, Germany; KLUG (German Alliance on Climate Change and Health), Berlin, Germany
10 shared publications - Claas Hinze
Department of Pediatric Rheumatology and Immunology, University Hospital Münster, Münster, Germany
9 shared publications Sabrina Fuehner
Department of Pediatric Rheumatology and Immunology University Children's Hospital Muenster Muenster Germany
8 shared publications
Latest Publications
- 9 November 2026
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 56 (11) , e70284
Clinical–Immunological Phenomapping in Recurrent Pericarditis: Disentangling Biological Traits, Inflammatory State and Treatment Exposure
Background: Phenotype‐oriented management is increasingly advocated in recurrent pericarditis (RP), but it remains unclear whether clinically recognizable phenotypes reflect underlying disease biology or are shaped by current inflammation and treatment exposure. We used multidimensional phenomapping to investigate this heterogeneity. Methods: We analysed 101 patients with idiopathic RP from the multicenter PERIPLO cohort. Factor analysis of mixed data followed by hierarchical clustering defined the index solution. Robustness was assessed across alternative specifications and models excluding treatment, inflammatory state or the IL‐1Ra axis. Results: Three clinical–immunological patterns emerged: a predominantly remission‐state, anakinra‐treated group; a predominantly remission‐state group largely managed without IL‐1 blockade; and an active inflammatory group enriched for anti‐IL‐1Ra autoantibodies and characterized by markedly reduced measured IL‐1Ra. The two antibody‐negative groups were extensively reorganized after treatment variables were removed, whereas exclusion of the IL‐1Ra axis nearly abolished agreement with the original partition. In contrast, anti‐IL‐1Ra positivity remained consistently associated with active inflammation and very low measured IL‐1Ra. Conclusions: In this cohort, the phenotypic heterogeneity of RP was better represented as a clinical–immunological spectrum shaped by inflammatory state and treatment exposure than as discrete, stable endotypes. The anti‐IL‐1Ra‐associated inflammatory signature was the most internally consistent biological signal. These exploratory findings require external validation, and longitudinal multidimensional phenomapping should test whether this signature can inform patient management.
- 9 November 2026
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 56 (11) , e70284
Clinical–Immunological Phenomapping in Recurrent Pericarditis: Disentangling Biological Traits, Inflammatory State and Treatment Exposure
Background: Phenotype‐oriented management is increasingly advocated in recurrent pericarditis (RP), but it remains unclear whether clinically recognizable phenotypes reflect underlying disease biology or are shaped by current inflammation and treatment exposure. We used multidimensional phenomapping to investigate this heterogeneity. Methods: We analysed 101 patients with idiopathic RP from the multicenter PERIPLO cohort. Factor analysis of mixed data followed by hierarchical clustering defined the index solution. Robustness was assessed across alternative specifications and models excluding treatment, inflammatory state or the IL‐1Ra axis. Results: Three clinical–immunological patterns emerged: a predominantly remission‐state, anakinra‐treated group; a predominantly remission‐state group largely managed without IL‐1 blockade; and an active inflammatory group enriched for anti‐IL‐1Ra autoantibodies and characterized by markedly reduced measured IL‐1Ra. The two antibody‐negative groups were extensively reorganized after treatment variables were removed, whereas exclusion of the IL‐1Ra axis nearly abolished agreement with the original partition. In contrast, anti‐IL‐1Ra positivity remained consistently associated with active inflammation and very low measured IL‐1Ra. Conclusions: In this cohort, the phenotypic heterogeneity of RP was better represented as a clinical–immunological spectrum shaped by inflammatory state and treatment exposure than as discrete, stable endotypes. The anti‐IL‐1Ra‐associated inflammatory signature was the most internally consistent biological signal. These exploratory findings require external validation, and longitudinal multidimensional phenomapping should test whether this signature can inform patient management.
- Open Access
- 27 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms
SARS-CoV-2 infection affects multiple immune mechanisms and leads to severe COVID-19 and death, in part related to infection-induced or pre-existing autoantibodies. Here, we describe severe COVID-19 to associate with autoantibodies against interleukin-1 receptor antagonist (IL-1Ra) and progranulin (PGRN), endogenous antagonists of IL-1 and TNF signaling, respectively. These autoantibodies coincide with hyperphosphorylation of IL-1Ra (Thr111) or PGRN (Ser81), form immune complexes independent of phosphorylation, reduce antigen plasma levels, and permit enhanced IL-1 and TNF signaling. Using phage-display selected Fabs specific for hyperphosphorylated isoforms, we track phospho-antigens and autoantibodies in a German national pandemic network cohort. Most seropositive patients show both autoantibodies. Levels peak at baseline and decline over 12 months, with phospho-antigens decreasing before autoantibodies. Seropositivity associates with hyperinflammation and cytokine profiles. Importantly, signaling by key inflammatory cytokines induce IL-1Ra and PGRN hyperphosphorylation in healthy monocytes, but require up to 1000-fold higher doses than in monocytes from previously seropositive severe COVID-19 survivors.
- 27 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessAutoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms
SARS-CoV-2 infection affects multiple immune mechanisms and leads to severe COVID-19 and death, in part related to infection-induced or pre-existing autoantibodies. Here, we describe severe COVID-19 to associate with autoantibodies against interleukin-1 receptor antagonist (IL-1Ra) and progranulin (PGRN), endogenous antagonists of IL-1 and TNF signaling, respectively. These autoantibodies coincide with hyperphosphorylation of IL-1Ra (Thr111) or PGRN (Ser81), form immune complexes independent of phosphorylation, reduce antigen plasma levels, and permit enhanced IL-1 and TNF signaling. Using phage-display selected Fabs specific for hyperphosphorylated isoforms, we track phospho-antigens and autoantibodies in a German national pandemic network cohort. Most seropositive patients show both autoantibodies. Levels peak at baseline and decline over 12 months, with phospho-antigens decreasing before autoantibodies. Seropositivity associates with hyperinflammation and cytokine profiles. Importantly, signaling by key inflammatory cytokines induce IL-1Ra and PGRN hyperphosphorylation in healthy monocytes, but require up to 1000-fold higher doses than in monocytes from previously seropositive severe COVID-19 survivors.
- Open Access
- 12 October 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (10) , e70110
Mapping Drivers of Coronary Endothelial Activation and Endothelial‐to‐Mesenchymal Transition through Mimicking of Multimediator Inflammation in Kawasaki Disease Context
Objective: Kawasaki disease (KD) is an acute systemic vasculitis predominantly affecting coronary arteries of infants and children. We recently identified leucin‐rich α‐2‐glycoprotein 1 (LRG‐1) as known transforming growth factor β1 (TGFβ1) signal‐modulating molecule, orchestrating endothelial activation and cardiac remodeling, as associated with interleukin‐1β (IL‐1β) signaling in KD. In the present study, we aimed to assess the role for LRG‐1 as part of a multimediator inflammatory environment as a possible direct mediator of human coronary artery endothelial activation. Methods: Human coronary artery endothelial cells (HCAECs) were treated with a blood inflammatory matrix, with or without targeted inhibition of several inflammatory mediators, including LRG‐1, and were analyzed for inflammatory activation or endothelial‐to‐mesenchymal transition (EndMT) on gene expression level. Proteomic profiling of the inflammatory matrix, treatment‐naïve KD (n = 11), or healthy control serum samples (n = 10) was performed by proximity extension assay (n = 184 markers) and Luminex. Results: Proteomic analysis of KD serum samples and the inflammatory matrix revealed elevation of 37 versus 50 inflammatory proteins, respectively, with 19 significantly up‐regulated markers shared. The HCAEC culture with the inflammatory matrix resulted in inflammatory endothelial activation, which was most efficiently abrogated by IL‐1 receptor type 1 (IL‐1R1) inhibition compared to all other tested drugs. Whereas inflammatory endothelial activation can also link to TGFβ‐driven EndMT, which was supported by respective signatures in our KD serum proteomics, we observed that in vitro inflammatory matrix–induced EndMT was partly impaired by both IL‐1R1 and tumor necrosis factor inhibition compared to other tested drugs. Conclusions: Collectively, our observations in the context of a multimediator inflammatory environment indicate a prominent role of a specific clinically relevant cytokine signaling axis in inflammatory coronary artery endothelial activation and EndMT in the context of KD.
- 12 October 2025
- Published by Wiley in ACR Open Rheumatology
- Vol. 7 (10) , e70110
Open AccessMapping Drivers of Coronary Endothelial Activation and Endothelial‐to‐Mesenchymal Transition through Mimicking of Multimediator Inflammation in Kawasaki Disease Context
Objective: Kawasaki disease (KD) is an acute systemic vasculitis predominantly affecting coronary arteries of infants and children. We recently identified leucin‐rich α‐2‐glycoprotein 1 (LRG‐1) as known transforming growth factor β1 (TGFβ1) signal‐modulating molecule, orchestrating endothelial activation and cardiac remodeling, as associated with interleukin‐1β (IL‐1β) signaling in KD. In the present study, we aimed to assess the role for LRG‐1 as part of a multimediator inflammatory environment as a possible direct mediator of human coronary artery endothelial activation. Methods: Human coronary artery endothelial cells (HCAECs) were treated with a blood inflammatory matrix, with or without targeted inhibition of several inflammatory mediators, including LRG‐1, and were analyzed for inflammatory activation or endothelial‐to‐mesenchymal transition (EndMT) on gene expression level. Proteomic profiling of the inflammatory matrix, treatment‐naïve KD (n = 11), or healthy control serum samples (n = 10) was performed by proximity extension assay (n = 184 markers) and Luminex. Results: Proteomic analysis of KD serum samples and the inflammatory matrix revealed elevation of 37 versus 50 inflammatory proteins, respectively, with 19 significantly up‐regulated markers shared. The HCAEC culture with the inflammatory matrix resulted in inflammatory endothelial activation, which was most efficiently abrogated by IL‐1 receptor type 1 (IL‐1R1) inhibition compared to all other tested drugs. Whereas inflammatory endothelial activation can also link to TGFβ‐driven EndMT, which was supported by respective signatures in our KD serum proteomics, we observed that in vitro inflammatory matrix–induced EndMT was partly impaired by both IL‐1R1 and tumor necrosis factor inhibition compared to other tested drugs. Conclusions: Collectively, our observations in the context of a multimediator inflammatory environment indicate a prominent role of a specific clinically relevant cytokine signaling axis in inflammatory coronary artery endothelial activation and EndMT in the context of KD.
- Open Access
The systemic JIA synovial fluid environment supports development and prevalence of specific inflammatory T helper cell phenotypes
Objective: The potential involvement of adaptive immunity in systemic juvenile idiopathic arthritis (sJIA) pathophysiology remains an intriguing question. Here, we investigated whether and how the inflammatory environment in sJIA versus JIA synovial fluid (SF) may differentially impact T helper (Th) cell polarization and activation. Methods: SF samples from sJIA and JIA patients (both n=7) were tested in various cell culture setups, with or without recombinant cytokines or cytokine-blocking drugs, to assess their effects on healthy donor Th cell activation. We analyzed cellular surface marker, transcription factor, and effector molecule expression using flow cytometry, Luminex, ELISA, and qRT-PCR. Results: Both sJIA and JIA SF revealed highly pro-inflammatory profiles. Compared to JIA, sJIA SF demonstrated markedly elevated IL-1β, IL-18, GM-CSF, S100A9, and MPO levels, while JIA SF showed trends toward higher soluble FasL and IL-17A concentrations. Notably, sJIA SF significantly increased CD4 T cell ICOS expression and expanded CXCR3 pos CCR6 pos Th cells, whereas JIA SF favored expansion of CXCR3 neg CCR6 pos Th cells and CCR6 pos Th cell expansion was sensitive to IL-1 blockade. Systemic JIA SF selectively sustained a IFNγ/IL-21 expressing T peripheral helper (Tph) phenotype, particularly associated with IL-1β, IL-18, and GM-CSF SF levels. Spiking JIA SF with a cocktail of these cytokines recapitulated some T cellular phenotypic features observed in sJIA SF cultures. Conclusion: JIA and sJIA SF drive distinct Th cell polarization, including differential and sustained Tf/ph cell activation. These findings complement our earlier observations in sJIA peripheral blood and demonstrate the impact of the SF inflammatory matrix on immune cell activation. What is already known on this topic: Systemic juvenile idiopathic arthritis (sJIA, Still’s Disease) is initially hallmarked by innate immunity driving systemic inflammation With further disease course sJIA can progress to chronic destructive arthritis with several studies suggesting an involvement of adaptive immunity in this process. In a previous study we linked T follicular/peripheral helper (Tfh/Tph) cells in sJIA patients’ blood to arthritis and self-reactive antibody signatures in patients with longer disease duration What this study adds: Our study demonstrates that sJIA versus JIA synovial fluid (SF) can drive differential T helper cell (Th cell) polarization and activation. Our data imply that sJIA SF promotes the self-sustenance of Th cells with a Tph phenotype characterized by IFNγ, IL-21 and c-MAF expression. IL-1β, IL-18, and GM-CSF levels in sJIA SF can be associated with Tph perseverance, and recapitulate sJIA Tph features when spiked into JIA SF. How this study might affect research, practice or policy: The present data complement our earlier observations from sJIA peripheral blood and strengthen the biphasic model hypothesis regarding sJIA progression While both JIA and sJIA patients can develop clinically similar arthritis, our data demonstrate how the respective local inflammatory environments can differentially impact and shape T cell immunity. Our data suggest a combined and early targeting of both IL-1β and IL-18 in sJIA may be effective in preventing the generation of inflammatory T cell subsets with the potential to drive chronic arthritis through a joint-localized, adaptive immune response.
Open AccessThe systemic JIA synovial fluid environment supports development and prevalence of specific inflammatory T helper cell phenotypes
Objective: The potential involvement of adaptive immunity in systemic juvenile idiopathic arthritis (sJIA) pathophysiology remains an intriguing question. Here, we investigated whether and how the inflammatory environment in sJIA versus JIA synovial fluid (SF) may differentially impact T helper (Th) cell polarization and activation. Methods: SF samples from sJIA and JIA patients (both n=7) were tested in various cell culture setups, with or without recombinant cytokines or cytokine-blocking drugs, to assess their effects on healthy donor Th cell activation. We analyzed cellular surface marker, transcription factor, and effector molecule expression using flow cytometry, Luminex, ELISA, and qRT-PCR. Results: Both sJIA and JIA SF revealed highly pro-inflammatory profiles. Compared to JIA, sJIA SF demonstrated markedly elevated IL-1β, IL-18, GM-CSF, S100A9, and MPO levels, while JIA SF showed trends toward higher soluble FasL and IL-17A concentrations. Notably, sJIA SF significantly increased CD4 T cell ICOS expression and expanded CXCR3 pos CCR6 pos Th cells, whereas JIA SF favored expansion of CXCR3 neg CCR6 pos Th cells and CCR6 pos Th cell expansion was sensitive to IL-1 blockade. Systemic JIA SF selectively sustained a IFNγ/IL-21 expressing T peripheral helper (Tph) phenotype, particularly associated with IL-1β, IL-18, and GM-CSF SF levels. Spiking JIA SF with a cocktail of these cytokines recapitulated some T cellular phenotypic features observed in sJIA SF cultures. Conclusion: JIA and sJIA SF drive distinct Th cell polarization, including differential and sustained Tf/ph cell activation. These findings complement our earlier observations in sJIA peripheral blood and demonstrate the impact of the SF inflammatory matrix on immune cell activation. What is already known on this topic: Systemic juvenile idiopathic arthritis (sJIA, Still’s Disease) is initially hallmarked by innate immunity driving systemic inflammation With further disease course sJIA can progress to chronic destructive arthritis with several studies suggesting an involvement of adaptive immunity in this process. In a previous study we linked T follicular/peripheral helper (Tfh/Tph) cells in sJIA patients’ blood to arthritis and self-reactive antibody signatures in patients with longer disease duration What this study adds: Our study demonstrates that sJIA versus JIA synovial fluid (SF) can drive differential T helper cell (Th cell) polarization and activation. Our data imply that sJIA SF promotes the self-sustenance of Th cells with a Tph phenotype characterized by IFNγ, IL-21 and c-MAF expression. IL-1β, IL-18, and GM-CSF levels in sJIA SF can be associated with Tph perseverance, and recapitulate sJIA Tph features when spiked into JIA SF. How this study might affect research, practice or policy: The present data complement our earlier observations from sJIA peripheral blood and strengthen the biphasic model hypothesis regarding sJIA progression While both JIA and sJIA patients can develop clinically similar arthritis, our data demonstrate how the respective local inflammatory environments can differentially impact and shape T cell immunity. Our data suggest a combined and early targeting of both IL-1β and IL-18 in sJIA may be effective in preventing the generation of inflammatory T cell subsets with the potential to drive chronic arthritis through a joint-localized, adaptive immune response.
- Open Access
- 30 May 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (6) , ytaf280
Anakinra during pregnancy and lactation for corticosteroid-dependant colchicine-resistant recurrent pericarditis in a patient with neutralizing anti-interleukin-1 receptor antagonist antibodies: a case report
Background: Anakinra, an interleukin-1 receptor antagonist (IL-1 Ra), is a treatment option for recurrent pericarditis refractory to conventional therapy. However, some patients cannot discontinue anakinra treatment without relapse. This is of particular concern for women of childbearing age, as data on its safety during pregnancy and lactation is limited. Case summary: We report the case of a 36-year-old White woman with recurrent pericarditis of an inflammatory phenotype. Pericardial biopsy revealed virus-negative fibro-productive pericarditis, and genetic testing showed no identifiable cause. Despite treatment with non-steroidal anti-inflammatory drugs, colchicine, and corticosteroids, the patient experienced multiple recurrences and developed corticosteroid-related side effects. Introduction of anakinra resulted in immediate clinical improvement and allowed corticosteroid withdrawal. However, several attempts to discontinue anakinra led to pericarditis recurrences. The patient tested positive for neutralizing anti-IL-1Ra antibodies. During the stable phase of the disease, as confirmed by cardiac magnetic resonance imaging, and while on anakinra and colchicine, she conceived spontaneously. She maintained anakinra treatment throughout the full-term pregnancy and breastfeeding, with no impact on foetal or child development. Discussion: Our paper provides evidence supporting the safe use of anakinra in pregnancy and lactation in a patient with recurrent pericarditis. It also reports the first case of anti-IL-1Ra antibodies in a patient receiving anakinra for recurrent pericarditis, which may help explain the dependency on the medication. The potential role of these antibodies as biomarkers for anakinra dependency or tools for optimizing immunosuppressive treatment warrants further research. A patient-centred counselling and a multidisciplinary approach are essential for achieving optimal outcomes.
- 30 May 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (6) , ytaf280
Open AccessAnakinra during pregnancy and lactation for corticosteroid-dependant colchicine-resistant recurrent pericarditis in a patient with neutralizing anti-interleukin-1 receptor antagonist antibodies: a case report
Background: Anakinra, an interleukin-1 receptor antagonist (IL-1 Ra), is a treatment option for recurrent pericarditis refractory to conventional therapy. However, some patients cannot discontinue anakinra treatment without relapse. This is of particular concern for women of childbearing age, as data on its safety during pregnancy and lactation is limited. Case summary: We report the case of a 36-year-old White woman with recurrent pericarditis of an inflammatory phenotype. Pericardial biopsy revealed virus-negative fibro-productive pericarditis, and genetic testing showed no identifiable cause. Despite treatment with non-steroidal anti-inflammatory drugs, colchicine, and corticosteroids, the patient experienced multiple recurrences and developed corticosteroid-related side effects. Introduction of anakinra resulted in immediate clinical improvement and allowed corticosteroid withdrawal. However, several attempts to discontinue anakinra led to pericarditis recurrences. The patient tested positive for neutralizing anti-IL-1Ra antibodies. During the stable phase of the disease, as confirmed by cardiac magnetic resonance imaging, and while on anakinra and colchicine, she conceived spontaneously. She maintained anakinra treatment throughout the full-term pregnancy and breastfeeding, with no impact on foetal or child development. Discussion: Our paper provides evidence supporting the safe use of anakinra in pregnancy and lactation in a patient with recurrent pericarditis. It also reports the first case of anti-IL-1Ra antibodies in a patient receiving anakinra for recurrent pericarditis, which may help explain the dependency on the medication. The potential role of these antibodies as biomarkers for anakinra dependency or tools for optimizing immunosuppressive treatment warrants further research. A patient-centred counselling and a multidisciplinary approach are essential for achieving optimal outcomes.
- Open Access
- 8 May 2024
- Published by Elsevier in Clinical Immunology
- Vol. 264, 110237
Proteomic mapping identifies serum marker signatures associated with MIS-C specific hyperinflammation and cardiovascular manifestation
- 8 May 2024
- Published by Elsevier in Clinical Immunology
- Vol. 264, 110237
Open AccessProteomic mapping identifies serum marker signatures associated with MIS-C specific hyperinflammation and cardiovascular manifestation
- Open Access
- 2 October 2023
- Published by Wiley in ACR Open Rheumatology
- Vol. 5 (12) , 652-662
Type 1 Interferon‐Stimulated Gene Expression and Disease Activity in Pediatric Rheumatic Diseases: No Composite Scores Needed?
Objective: Rheumatic diseases are characterized by different patterns of immune overactivation. This study investigated the correlation of whole blood type 1 interferon (IFN) stimulated gene (ISG), IL18, and CXCL9 expression with clinical disease activity in pediatric rheumatic diseases and assessed the required number of ISGs to be included in a composite type 1 IFN score.Methods: Whole blood‐derived RNA and clinical data were collected from 171 mostly pediatric patients with connective tissue diseases (CTDs), systemic autoinflammatory diseases (SAIDs), monogenic interferonopathies (IFNPs) and other inflammatory diseases, and from 38 controls. The expression of six previously established ISGs, IL18, and CXCL9 was assessed by real‐time polymerase chain reaction (471 samples). Individual and composite gene expression was assessed, and correlation and threshold analyses were performed.Results: Correlation between ISG expression and clinical disease activity was strongest in CTD, especially in juvenile dermatomyositis (JDM) and IFNP, and modest in patients with SAID. Threshold ISG expression levels for the detection of at least mild clinical disease activity were substantially higher in patients with systemic lupus erythematosus compared with JDM. The correlation of expression levels of limited sets of ISGs and even individual ISGs with clinical disease activity were not inferior to a composite score of six ISGs.Conclusion: In a real‐world cohort, individual ISG expression levels robustly reflected clinical disease activity in CTD and IFNP, especially in JDM, which would simplify such analyses in clinical routine and be more cost‐effective. Threshold levels varied across diseases, potentially reflecting different mechanisms of type 1 IFN overactivation.
- 2 October 2023
- Published by Wiley in ACR Open Rheumatology
- Vol. 5 (12) , 652-662
Open AccessType 1 Interferon‐Stimulated Gene Expression and Disease Activity in Pediatric Rheumatic Diseases: No Composite Scores Needed?
Objective: Rheumatic diseases are characterized by different patterns of immune overactivation. This study investigated the correlation of whole blood type 1 interferon (IFN) stimulated gene (ISG), IL18, and CXCL9 expression with clinical disease activity in pediatric rheumatic diseases and assessed the required number of ISGs to be included in a composite type 1 IFN score.Methods: Whole blood‐derived RNA and clinical data were collected from 171 mostly pediatric patients with connective tissue diseases (CTDs), systemic autoinflammatory diseases (SAIDs), monogenic interferonopathies (IFNPs) and other inflammatory diseases, and from 38 controls. The expression of six previously established ISGs, IL18, and CXCL9 was assessed by real‐time polymerase chain reaction (471 samples). Individual and composite gene expression was assessed, and correlation and threshold analyses were performed.Results: Correlation between ISG expression and clinical disease activity was strongest in CTD, especially in juvenile dermatomyositis (JDM) and IFNP, and modest in patients with SAID. Threshold ISG expression levels for the detection of at least mild clinical disease activity were substantially higher in patients with systemic lupus erythematosus compared with JDM. The correlation of expression levels of limited sets of ISGs and even individual ISGs with clinical disease activity were not inferior to a composite score of six ISGs.Conclusion: In a real‐world cohort, individual ISG expression levels robustly reflected clinical disease activity in CTD and IFNP, especially in JDM, which would simplify such analyses in clinical routine and be more cost‐effective. Threshold levels varied across diseases, potentially reflecting different mechanisms of type 1 IFN overactivation.
- Open Access
- 17 March 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (5) , 826-841
Aberrant Naive CD4–Positive T Cell Differentiation in Systemic Juvenile Idiopathic Arthritis Committed to B Cell Help
Objective: Systemic juvenile idiopathic arthritis (JIA) features characteristics of autoinflammation and autoimmunity, culminating in chronic arthritis. In this study, we hypothesized that aberrant or incomplete polarization of T helper cells contributes to disease pathology.Methods: Cells or serum samples were obtained from healthy controls (n = 72) and systemic JIA patients (n = 171). Isolated naive T helper cells were cultured under Th1, Th17, and T follicular helper (Tfh) or T peripheral helper (Tph)—polarizing conditions and were partly cocultured with allogenic memory B cells. Cell samples were then analyzed for surface marker, transcription factor, and cytokine expression, as well as plasmablast generation. Serum samples were subjected to multiplexed bead and self‐antigen arrays and enzyme‐linked immunosorbent assays, and all data were compared to retrospective RNA profiling analyses.Results: Differentiation of systemic JIA–naive T helper cells toward Th1 cells resulted in low expression levels of interferon‐γ (IFNγ) and eomesodermin, which was associated in part with disease duration. In contrast, developing Th1 cells in patients with systemic JIA were found to produce elevated levels of interleukin‐21 (IL‐21), which negatively correlated with cellular expression of IFNγ and eomesodermin. In both in vitro and ex vivo analyses, IL‐21 together with programmed cell death 1 (PD‐1), inducible T cell costimulator (ICOS), and CXCR5 expression induced naive T helper cells from systemic JIA patients to polarize toward a Tfh/Tph cell phenotype. Retrospective analysis of whole‐blood RNA‐sequencing data demonstrated that Bcl‐6, a master transcription factor in Tfh/Tph cell differentiation, was overexpressed specifically in patients with systemic JIA. Naive T helper cells from systemic JIA patients which were stimulated in vitro promoted B cellular plasmablast generation, and self‐antigen array data indicated that IgG reactivity profiles of patients with systemic JIA differed from those of healthy controls.Conclusion: In the pathogenesis of systemic JIA, skewing of naive T helper cell differentiation toward a Tfh/Tph cell phenotype may represent an echo of autoimmunity, which may indicate the mechanisms driving progression toward chronic destructive arthritis. image
- 17 March 2023
- Published by Wiley in Arthritis & Rheumatology
- Vol. 75 (5) , 826-841
Open AccessAberrant Naive CD4–Positive T Cell Differentiation in Systemic Juvenile Idiopathic Arthritis Committed to B Cell Help
Objective: Systemic juvenile idiopathic arthritis (JIA) features characteristics of autoinflammation and autoimmunity, culminating in chronic arthritis. In this study, we hypothesized that aberrant or incomplete polarization of T helper cells contributes to disease pathology.Methods: Cells or serum samples were obtained from healthy controls (n = 72) and systemic JIA patients (n = 171). Isolated naive T helper cells were cultured under Th1, Th17, and T follicular helper (Tfh) or T peripheral helper (Tph)—polarizing conditions and were partly cocultured with allogenic memory B cells. Cell samples were then analyzed for surface marker, transcription factor, and cytokine expression, as well as plasmablast generation. Serum samples were subjected to multiplexed bead and self‐antigen arrays and enzyme‐linked immunosorbent assays, and all data were compared to retrospective RNA profiling analyses.Results: Differentiation of systemic JIA–naive T helper cells toward Th1 cells resulted in low expression levels of interferon‐γ (IFNγ) and eomesodermin, which was associated in part with disease duration. In contrast, developing Th1 cells in patients with systemic JIA were found to produce elevated levels of interleukin‐21 (IL‐21), which negatively correlated with cellular expression of IFNγ and eomesodermin. In both in vitro and ex vivo analyses, IL‐21 together with programmed cell death 1 (PD‐1), inducible T cell costimulator (ICOS), and CXCR5 expression induced naive T helper cells from systemic JIA patients to polarize toward a Tfh/Tph cell phenotype. Retrospective analysis of whole‐blood RNA‐sequencing data demonstrated that Bcl‐6, a master transcription factor in Tfh/Tph cell differentiation, was overexpressed specifically in patients with systemic JIA. Naive T helper cells from systemic JIA patients which were stimulated in vitro promoted B cellular plasmablast generation, and self‐antigen array data indicated that IgG reactivity profiles of patients with systemic JIA differed from those of healthy controls.Conclusion: In the pathogenesis of systemic JIA, skewing of naive T helper cell differentiation toward a Tfh/Tph cell phenotype may represent an echo of autoimmunity, which may indicate the mechanisms driving progression toward chronic destructive arthritis. image
- 8 February 2023
- Published by Elsevier
- p. 351-368
Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19
- 8 February 2023
- Published by Elsevier
- p. 351-368
Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19
- Open Access
- 14 June 2022
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 42 (6) , 1330-1341
An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial
Purpose: A recent phase II open-label study of the interleukin 1 (IL-1) receptor antagonist (IL-1Ra) anakinra in treating IVIG-resistant Kawasaki disease (KD) patients reported promising results. Here, we aimed to characterize the immunological impact of IL-1 blockade in this unique study population. Methods: Patients’ and control sera and supernatants of cells (whole blood, neutrophils, coronary artery endothelial cells) stimulated with recombinant IL-1β were analyzed for single or multiple marker (n = 22) expression by ELISA or multiplexed bead array assay. Data were analyzed using unsupervised hierarchical clustering, multiple correlation, and multi-comparison statistics and were compared to retrospective analyses of KD transcriptomics. Results: Inflammation in IVIG-resistant KD (n = 16) is hallmarked by over-expression of innate immune mediators (particularly IL-6 > CXCL10 > S100A12 > IL-1Ra). Those as well as levels of immune or endothelial cell activation markers (sICAM-1, sVCAM-1) declined most significantly in course of anakinra treatment. Prior as well as following IL-1R blockade, over-expression of leucine-rich-α2-glycoprotein 1 (LRG1) associated best with remnant inflammatory activity and the necessity to escalate anakinra dosage and separated inflammatory KD patients from sJIA-MAS (n = 13) and MIS-C (n = 4). Protein as well as retrospective gene expression analyses indicated tight association of LRG1 with IL-1β signaling and neutrophilia, while particularly neutrophil stimulation with recombinant IL-1β resulted in concentration-dependent LRG1 release. Conclusion: Our study identifies LRG1 as known trigger of endothelial activation and cardiac re-modeling to associate with IL-1β signaling in KD. Besides a potential patho-mechanistic implication of these findings, our data suggest blood leukocyte and neutrophil counts to best predict response to IL-1Ra treatment in IVIG-resistant KD.
- 14 June 2022
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 42 (6) , 1330-1341
Open AccessAn Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial
Purpose: A recent phase II open-label study of the interleukin 1 (IL-1) receptor antagonist (IL-1Ra) anakinra in treating IVIG-resistant Kawasaki disease (KD) patients reported promising results. Here, we aimed to characterize the immunological impact of IL-1 blockade in this unique study population. Methods: Patients’ and control sera and supernatants of cells (whole blood, neutrophils, coronary artery endothelial cells) stimulated with recombinant IL-1β were analyzed for single or multiple marker (n = 22) expression by ELISA or multiplexed bead array assay. Data were analyzed using unsupervised hierarchical clustering, multiple correlation, and multi-comparison statistics and were compared to retrospective analyses of KD transcriptomics. Results: Inflammation in IVIG-resistant KD (n = 16) is hallmarked by over-expression of innate immune mediators (particularly IL-6 > CXCL10 > S100A12 > IL-1Ra). Those as well as levels of immune or endothelial cell activation markers (sICAM-1, sVCAM-1) declined most significantly in course of anakinra treatment. Prior as well as following IL-1R blockade, over-expression of leucine-rich-α2-glycoprotein 1 (LRG1) associated best with remnant inflammatory activity and the necessity to escalate anakinra dosage and separated inflammatory KD patients from sJIA-MAS (n = 13) and MIS-C (n = 4). Protein as well as retrospective gene expression analyses indicated tight association of LRG1 with IL-1β signaling and neutrophilia, while particularly neutrophil stimulation with recombinant IL-1β resulted in concentration-dependent LRG1 release. Conclusion: Our study identifies LRG1 as known trigger of endothelial activation and cardiac re-modeling to associate with IL-1β signaling in KD. Besides a potential patho-mechanistic implication of these findings, our data suggest blood leukocyte and neutrophil counts to best predict response to IL-1Ra treatment in IVIG-resistant KD.